Identification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma

被引：0

作者：

Manfredi, G. F. ^{[1
,2
]}

Fulgenzi, C. A. M. ^{[2
]}

D'Alessio, A. ^{[2
,3
]}

Celsa, C. ^{[2
,4
,5
]}

Stefanini, B. ^{[2
,6
]}

Cheon, J. ^{[7
]}

Ang, C. ^{[8
]}

Marron, T. U. ^{[8
]}

Saeed, A. ^{[9
]}

Wietharn, B. ^{[9
]}

Pressiani, T. ^{[10
]}

Pinter, M. ^{[11
]}

Scheiner, B. ^{[11
]}

Huang, Yi-Hsiang ^{[12
,13
]}

Phen, S. ^{[14
]}

Naqash, A. Rafeh ^{[15
]}

Piscaglia, F. ^{[6
]}

Lin, R. Po-Ting ^{[16
,17
]}

Lin, C. -yen ^{[16
,17
]}

Dalbeni, A. ^{[18
,19
]}

Vivaldi, C. ^{[20
,21
]}

Masi, G. ^{[20
,21
]}

Thimme, R. ^{[22
]}

Vogel, A. ^{[23
,24
,25
]}

Schonlein, M. ^{[26
]}

von Felden, J. ^{[27
]}

Schulze, K. ^{[27
]}

Wege, H. ^{[27
]}

Galle, P. R. ^{[28
]}

Kudo, M. ^{[29
]}

Rimassa, L. ^{[10
,30
]}

Singal, A. ^{[14
]}

Sharma, R. ^{[2
]}

Cortellini, A. ^{[1
,31
]}

Chon, H. Jae ^{[7
]}

Burlone, M. ^{[32
]}

Pirisi, M. ^{[1
,32
]}

Pinato, D. J. ^{[2
,3
]}

机构：

[1] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

[2] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London, England

[3] Univ Piemonte Orientale, Div Oncol, Dept Translat Med, Novara, Italy

[4] Univ Palermo, Sect Gastroenterol & Hepatol, Dept Hlth Promot Mother & Child Care Internal Med, Palermo, Italy

[5] Univ Palermo, Dept Surg Oncol & Oral Sci Di Chir On S, Palermo, Italy

[6] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[7] CHA Univ, Dept Internal Med, CHA Bundang Med Ctr, Med Oncol, Seongnam, South Korea

[8] Tisch Canc Inst, Mt Sinai Hosp, Div Hematol Oncol, Dept Med, New York, NY USA

[9] Kansas Univ, Div Med Oncol, Dept Med, Canc Ctr, Kansas City, KS USA

[10] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Via A Manzoni 56, I-20089 Rozzano, Milan, Italy

[11] Med Univ Vienna, Div Gastroenterol & Hepatol, Dept Internal Med 3, Vienna, Austria

[12] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Dept Med, Taipei, Taiwan

[13] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Sch Med, Taipei, Taiwan

[14] Univ Texas Southwestern Med Ctr, Dept Internal Med, Dallas, TX USA

[15] Univ Oklahoma, Med Oncol, Stephenson Canc Ctr, TSET Phase 1 Program, Oklahoma City, OK USA

[16] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Linkou Med Ctr, Taoyuan, Taiwan

[17] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[18] Univ Verona, Dept Med, Gen Med C Unit, Verona, Italy

[19] Univ Verona, Liver Unit, Verona, Italy

[20] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[21] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy

[22] Univ Freiburg, Freiburg Univ Med Ctr, Dept Med Gastroenterol Hepatol Endocrinol & Infec, Fac Med, Freiburg, Germany

[23] UHN, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada

[24] Princess Margaret Canc Ctr, Toronto, ON, Canada

[25] Hannover Med Sch, Hannover, Germany

[26] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany

[27] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Hamburg, Germany

[28] Univ Med Ctr Mainz, Dept Internal Med 1, Mainz, Germany

[29] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[30] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Milan, Italy

[31] Fdn Policlin Univ Campus Biomed, Med Oncol, Rome, Italy

[32] AOU Maggiore Carita, Div Internal Med, Novara, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷

关键词：

D O I：

10.1016/j.dld.2024.01.012

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

OC-11

引用

页码：S8 / S9

页数：2

共 50 条

[31] Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma
Ishihara, Nobuaki
Komatsu, Shohei
Sofue, Keitaro
Ueshima, Eisuke
Yano, Yoshihiko
Fujishima, Yoshimi
Ishida, Jun
Kido, Masahiro
Gon, Hidetoshi
Fukushima, Kenji
Urade, Takeshi
Yanagimoto, Hiroaki
Toyama, Hirochika
Ueda, Yoshihide
Kodama, Yuzo
Murakami, Takamichi
Fukumoto, Takumi
HEPATOLOGY RESEARCH, 2024, 54 (08) : 773 - 780
[32] Polymyalgia rheumatica during combination therapy with atezolizumab plus bevacizumab for advanced hepatocellular carcinoma
Dosoden, Naoki
Kuzuya, Teiji
Ito, Yumi
Nishino, Jo
Ohno, Eizaburo
Kawabe, Naoto
Hashimoto, Senju
Hirooka, Yoshiki
Yasuoka, Hidekata
CLINICAL JOURNAL OF GASTROENTEROLOGY, 2023, 16 (04) : 567 - 571
[33] CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study
Ueno, Masayuki
Takeda, Haruhiko
Takai, Atsushi
Morimura, Hiroki
Nishijima, Norihiro
Iwamoto, Satoru
Okuyama, Shunsuke
Umeda, Makoto
Seta, Takeshi
Ikeda, Atsuyuki
Goto, Tomoyuki
Miyamoto, Shin'ichi
Kayahara, Takahisa
Uenoyama, Yoshito
Matsumura, Kazuyoshi
Nakano, Shigeharu
Mishima, Masako
Inuzuka, Tadashi
Eso, Yuji
Takahashi, Ken
Marusawa, Hiroyuki
Osaki, Yukio
Hatano, Etsuro
Seno, Hiroshi
JOURNAL OF GASTROENTEROLOGY, 2024, 59 (12) : 1107 - 1118
[34] Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study
Kai, Machiko
Hikita, Hayato
Kazuki, Maesaka
Tahata, Yuki
Shinkai, Kazuma
Doi, Akira
Ohkawa, Kazuyoshi
Miyazaki, Masanori
Ishida, Hisashi
Matsumoto, Kengo
Nozaki, Yasutoshi
Yakushijin, Takayuki
Sakamori, Ryotaro
Kaneko, Akira
Iio, Sadaharu
Nawa, Takatoshi
Kakita, Naruyasu
Morishita, Naoki
Hiramatsu, Naoki
Usui, Takeo
Imanaka, Kazuho
Doi, Yoshinori
Sakakibara, Mitsuru
Yoshida, Yuichi
Oze, Tsugiko
Kodama, Takahiro
Tatsumi, Tomohide
Takehara, Tetsuo
PLOS ONE, 2024, 19 (01):
[35] CLINICAL FACTORS ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY
Maesaka, Kazuki
Hikita, Hayato
Kai, Machiko
Tahata, Yuki
Shinkai, Kazuma
Doi, Akira
Ohkawa, Kazuyoshi
Miyazaki, Masanori
Ishida, Hisashi
Matsumoto, Kengo
Nozaki, Yasutoshi
Yakushijin, Takayuki
Sakamori, Ryotaro
Kodama, Takahiro
Tatsumi, Tomohide
Takehara, Tetsuo
HEPATOLOGY, 2023, 78 : S1813 - S1813
[36] The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
Esmail, Abdullah
Xu, Jiaqiong
Burns, Ethan A.
Abboud, Karen
Sheikh, Ali
Umoru, Godsfavour
Gee, Kelly
Wiechmann, Catherine
Zhang, Yuqi
Abdelrahim, Maen
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
[37] Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma
Itoh, Shinji
Ikeda, Masafumi
HEPATOBILIARY SURGERY AND NUTRITION, 2022,
[38] Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Reika Yamauchi
Takanori Ito
Sachiyo Yoshio
Takafumi Yamamoto
Kazuyuki Mizuno
Masatoshi Ishigami
Hiroki Kawashima
Satoshi Yasuda
Shigeo Shimose
Hideki Iwamoto
Taiji Yamazoe
Taizo Mori
Eiji Kakazu
Takumi Kawaguchi
Hidenori Toyoda
Tatsuya Kanto
Journal of Gastroenterology, 2023, 58 : 565 - 574
[39] Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Yamauchi, Reika
Ito, Takanori
Yoshio, Sachiyo
Yamamoto, Takafumi
Mizuno, Kazuyuki
Ishigami, Masatoshi
Kawashima, Hiroki
Yasuda, Satoshi
Shimose, Shigeo
Iwamoto, Hideki
Yamazoe, Taiji
Mori, Taizo
Kakazu, Eiji
Kawaguchi, Takumi
Toyoda, Hidenori
Kanto, Tatsuya
JOURNAL OF GASTROENTEROLOGY, 2023, 58 (06) : 565 - 574
[40] Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Yamauchi, Yurika
Saeki, Issei
Yamasaki, Takahiro
Egusa, Maho
Nishiyama, Natsuko
Fujioka, Tsuyoshi
Kawamoto, Daiki
Nishimura, Tatsuro
Tanabe, Norikazu
Oono, Takashi
Matsumoto, Toshihiko
Ishikawa, Tsuyoshi
Marumoto, Yoshio
Matsukuma, Satoshi
Shindo, Yoshitaro
Tokumitsu, Yukio
Yoshimine, Sota
Murakami, Junichi
Tanaka, Toshiki
Kimura, Sotai
Hoshii, Yoshinobu
Hamano, Kimikazu
Nagano, Hiroaki
Takami, Taro
HEPATOLOGY RESEARCH, 2023, 53 (07) : 681 - 686

← 1 2 3 4 5 →